Neural immunoregulation of post-traumatic autoimmunity

创伤后自身免疫的神经免疫调节

基本信息

  • 批准号:
    10522859
  • 负责人:
  • 金额:
    $ 52.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-01 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

Chronic low back pain (LBP) and osteoarthritic (OA) joint pain are the most common causes of chronic disabling pain and despite extensive investigation the pathophysiology of these conditions remains undefined and there is considerable controversy regarding their clinical management. Clearly current hypotheses for the progression of tissue injury to painful disability have not, short of removing the painful joint from the body, generated effective and safe treatments. Our recent studies in the mouse tibia fracture model of complex regional pain syndrome (CRPS) demonstrated that all CRPS patients expressed IgM autoantibodies with pronociceptive passive transfer effects after intraplantar injection into the injured hindlimb or intrathecal injection into muMT fracture mice lacking B cells and immunoglobulin, and these pronociceptive CRPS IgM effects were mediated by C5a complement signaling and inflammatory cytokine release. Tibia fracture in mice caused an increase of C5a receptor (C5aR) expressing macrophages in the fracture limb dermis and C5aR expressing microglia in the corresponding spinal cord segments, and these activated immune cells release pronociceptive inflammatory cytokines in response to C5a signaling. Moreover, after fracture in mice, exaggerated neuropeptide and sympathetic adrenergic signaling stimulated pronociceptive IgM antibody accumulation in the skin and spinal cord. These observations are potentially paradigm shifting. The central hypothesis guiding our work is that tissue trauma causes neural activation of the innate and adaptive systems of immunity, with localized neoantigen expression in the injured tissue and corresponding spinal cord triggering lymph organ germinal center reactions characterized by the formation germinal B cells, with subsequent pronociceptive immune complex deposition and complement activation supporting localized chronic nociceptive sensitization. The primary objective of this proposal is to identify specific pharmacologic targets for the successful treatment of LBP and OA. The specific aims are; 1) to identify the autoimmune responses mediating nociceptive sensitization in the lumbar disc puncture (DP) mouse model of chronic LBP and in the monosodium iodoacetate arthritis (MIA) mouse model of chronic OA knee pain, to determine the prevalence of pronociceptive antibodies in LBP and OA patients, and to identify adaptive immune responses in LBP patient spinal discs and OA patient joints, 2) to temporally map the formation of lymph node germinal centers, characterized by the induction of T follicular helper cells (Tfh), germinal center B cells, and the production of pronociceptive antibodies in the DP and MIA mouse models, and 3) to determine whether sensory neuropeptide and sympathetic adrenergic signaling constitute a unifying mechanism for the activation and maintenance of the immune response to tissue injury. These experiments potentially will establish a rigorous foundation for exploring mechanisms of tissue injury induced autoimmunity, advance our understanding of musculoskeletal pain, and identify specific targets for future clinical trials.
慢性腰痛(LBP)和骨关节炎(OA)关节疼痛是慢性腰痛(LBP)的最常见原因。 致残性疼痛,尽管进行了广泛的研究,但这些疾病的病理生理学仍不明确 并且关于它们的临床管理存在相当大的争议。显然,目前的假设, 组织损伤到疼痛性残疾的进展,除了从身体上移除疼痛的关节, 产生了有效和安全的治疗方法。我们最近在小鼠胫骨复杂骨折模型的研究 局部疼痛综合征(CRPS)显示,所有CRPS患者均表达IgM自身抗体, 足底或鞘内注射致痛性被动传递效应 注射到缺乏B细胞和免疫球蛋白的muMT骨折小鼠中, 作用由C5a补体信号传导和炎性细胞因子释放介导。小鼠胫骨骨折 引起骨折肢真皮中表达C5a受体(C5aR)的巨噬细胞增加, 在相应的脊髓节段中表达小胶质细胞,这些激活的免疫细胞释放 对C5a信号传导作出响应的致伤害性炎性细胞因子。此外,小鼠骨折后, 增强的神经肽和交感肾上腺素能信号刺激的原伤害感受IgM抗体 在皮肤和脊髓中积累。这些观察结果可能会改变范式。中央 指导我们工作的假设是,组织创伤引起先天和适应性系统的神经激活 在损伤组织和相应的脊髓中有局部新抗原表达 引发淋巴器官生殖中心反应,其特征在于形成生殖B细胞, 随后的原伤害性免疫复合物沉积和补体激活支持局部 慢性伤害性致敏该提案的主要目的是确定特定的药理学 成功治疗LBP和OA的靶点。具体目的是:1)识别自身免疫性 慢性LBP腰椎间盘穿刺(DP)小鼠模型中介导伤害性敏化的反应 以及在慢性OA膝关节疼痛的碘乙酸盐关节炎(MIA)小鼠模型中, 在LBP和OA患者中的原伤害感受抗体的患病率,并确定LBP和OA患者中的适应性免疫应答。 LBP患者的椎间盘和OA患者的关节,2)时间映射淋巴结转移的形成 中心,其特征在于诱导T滤泡辅助细胞(Tfh)、生发中心B细胞和 在DP和MIA小鼠模型中产生原伤害感受抗体,和3)确定是否 感觉神经肽和交感肾上腺素能信号传导构成了统一的激活机制 和维持对组织损伤的免疫应答。这些实验可能会建立一个 为探索组织损伤诱导自身免疫的机制奠定了坚实的基础, 了解肌肉骨骼疼痛,并确定未来临床试验的具体目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID J. CLARK其他文献

DAVID J. CLARK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID J. CLARK', 18)}}的其他基金

rTMS in alleviating Pain and Co-morbid symptoms in GWVI
rTMS 缓解 GWVI 的疼痛和共病症状
  • 批准号:
    10295159
  • 财政年份:
    2019
  • 资助金额:
    $ 52.82万
  • 项目类别:
rTMS in alleviating Pain and Co-morbid symptoms in GWVI
rTMS 缓解 GWVI 的疼痛和共病症状
  • 批准号:
    10041709
  • 财政年份:
    2019
  • 资助金额:
    $ 52.82万
  • 项目类别:
rTMS in alleviating Pain and Co-morbid symptoms in GWVI
rTMS 缓解 GWVI 的疼痛和共病症状
  • 批准号:
    10578659
  • 财政年份:
    2019
  • 资助金额:
    $ 52.82万
  • 项目类别:
Traumatic Brain Injury and Endogenous Pain Modulation
创伤性脑损伤和内源性疼痛调节
  • 批准号:
    10329882
  • 财政年份:
    2016
  • 资助金额:
    $ 52.82万
  • 项目类别:
Pain after Trauma and TBI: Epigenetic Mechanisms
创伤和创伤性脑损伤后的疼痛:表观遗传机制
  • 批准号:
    9215534
  • 财政年份:
    2016
  • 资助金额:
    $ 52.82万
  • 项目类别:
Pain after Trauma and TBI: Epigenetic Mechanisms
创伤和创伤性脑损伤后的疼痛:表观遗传机制
  • 批准号:
    9076504
  • 财政年份:
    2016
  • 资助金额:
    $ 52.82万
  • 项目类别:
Neural Immunoregulation of Post-Traumatic Autoimmunity
创伤后自身免疫的神经免疫调节
  • 批准号:
    9765423
  • 财政年份:
    2016
  • 资助金额:
    $ 52.82万
  • 项目类别:
Neural Immunoregulation of Post-Traumatic Autoimmunity
创伤后自身免疫的神经免疫调节
  • 批准号:
    9172811
  • 财政年份:
    2016
  • 资助金额:
    $ 52.82万
  • 项目类别:
Traumatic Brain Injury and Endogenous Pain Modulation
创伤性脑损伤和内源性疼痛调节
  • 批准号:
    10552600
  • 财政年份:
    2016
  • 资助金额:
    $ 52.82万
  • 项目类别:
Neural immunoregulation of post-traumatic autoimmunity
创伤后自身免疫的神经免疫调节
  • 批准号:
    10698029
  • 财政年份:
    2016
  • 资助金额:
    $ 52.82万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 52.82万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 52.82万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 52.82万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.82万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 52.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 52.82万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 52.82万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 52.82万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 52.82万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 52.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了